Reinhard von Roemeling
Hoofd Techniek/Wetenschap/O&O bij CURIS, INC.
Profiel
Reinhard von Roemeling is currently the Senior Vice President-Clinical Development at Curis, Inc. He was previously the Global Head-Research & Development at HUYA Bioscience International LLC.
Dr. von Roemeling holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Actieve functies van Reinhard von Roemeling
| Bedrijven | Functie | Begin |
|---|---|---|
| CURIS, INC. | Hoofd Techniek/Wetenschap/O&O | 13-08-2019 |
Eerdere bekende functies van Reinhard von Roemeling
| Bedrijven | Functie | Einde |
|---|---|---|
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Reinhard von Roemeling
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |